The goals of the American Chemical Society Petroleum Research Fund are:

• To support fundamental research in the petroleum field, and
• To develop the next generation of engineers and scientists through support of advanced scientific education.

The Undergraduate Research (UR) grants program supports the research programs of established scientists and engineers at non-doctoral departments and provides financial support for students at those institutions to become involved in advanced research activities, in preparation for continued study in graduate school or employment.

The New Directions (ND) grants program provides funds to scientists and engineers with limited—or even no—preliminary results for a research project they wish to pursue, and who intend to use the PRF-driven preliminary results to seek continuation funding from other agencies. ND grants are to be used to illustrate proof of concept/feasibility. Accordingly, they are to be viewed as seed money for new research ventures.

A "new research direction" is something different from previous research performed by the lead principal investigator (lead PI). But, it may involve a field of science or engineering in which others are already working. Therefore, the proposed research should not be in the same direction as—or overlap with—current projects in the lead PI’s research group. Excluded from consideration will be

• Lead PIs who have had previous support or current funding for the project, and
• Proposals presenting ideas that are a logical extension of ongoing research from the lead PI’s laboratory.

Preliminary results and/or communications are not required.

The Next Generation Pregnancy Initiative supports research in the following priority areas:

• Biological mechanisms of healthy pregnancy, including the normal physiology and biological underpinnings of health pregnancy
• Preterm birth
• Pregnancy loss after 12 weeks of gestation, including recurrent pregnancy loss
• Preeclampsia

Bleeding Disorders Canada, formerly the Canadian Hemophilia Society (CHS), is proud to announce its call for applications for its research programs for the 2026–2027 grant period.

The Canadian Hemophilia Society became Bleeding Disorders Canada in July 2026. During this transition period, research grant documents may include references to both Bleeding Disorders Canada and the Canadian Hemophilia Society (CHS) as we update our materials to reflect our new name.

The deadline to submit applications for all the programs is NOVEMBER 27, 2026. Please see below details of each research grant and links to apply. Feel free to reach out to Natalie Philbert, National Programs Director, if you have any questions or require assistance at nphilbert@hemophilia.ca.

DREAM OF A CURE

The CHS provides scientific research grants and studentships aimed at developing treatments for hemophilia A and B, von Willebrand disease, rare factor deficiencies, and platelet function disorders.

Individual grants valued at $75,000 per year and per project will be awarded to researchers for a maximum of $150,000 which can be expended over 2 or 3 years.

Grants will also be available for Canadian medical or science students for up to 4 months, for a maximum stipend of $6,000 each.

Examples of previous research awarded include: Human Endometrial Endothelial Cells (HEECs): A novel cellular method for understanding the pathophysiology of heavy menstrual bleeding in von Willebrand Disease by Dr. Mackenzie Bowman & Dr. Paula James

Online applications for the 2026-27 granting period, previous and current research, as well as the general criteria and conditions can be accessed at: www.hemophilia.ca/chs-dream-of-a-cure-research-program.

______________________________

PFIZER CARE UNTIL CURE RESEARCH PROGRAM

In partnership with Pfizer, the CHS provides research grants to Canadian investigators to conduct research on medical and psychosocial aspects of bleeding disorders, including hemophilia, people with von Willebrand disease or other inherited bleeding disorders, people with related conditions such as HIV or hepatitis C infection, and carriers of an inherited bleeding disorder.

Individual grants valued at $75,000 per year and per project will be awarded to researchers for a maximum of $150,000 which can be expended over 2 or 3 years.

Examples of previous research awarded include: A Canadian Roadmap and Action Plan for Hemophilia Gene Therapies: A Mixed-Method Study by Dr. Roy Khalifé

Online application forms for the 2026-27 granting period, previous and current research, general criteria and specific areas of interest can be accessed at: www.hemophilia.ca/the-chspfizer-care-until-cure-research-program

Please feel free to distribute this information to others who may be interested in applying. The research must be conducted in Canada by researchers affiliated with Canadian universities and not-for-profit-related organizations.

The Project Grant program is expected to:

• Support a diverse portfolio of health-related research and knowledge translation proposals at any stage, from discovery to application, including commercialization;
• Promote relevant collaborations across disciplines, professions, and sectors; and
• Contribute to the creation and use of health-related knowledge.

The PCC Fellowship Program supports qualified scientists interested in the field of anti-doping, committed to meaningful research, and demonstrating potential for long-term contribution to the field of anti-doping scien​ce. Fellows selected by the PCC participate in a two-year program. Fellows gain practical knowledge from a U.S.-based, WADA-accredited laboratory and conduct research supporting the anti-doping field.